QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
Free Trial
NASDAQ:ALTH

Allos Therapeutics (ALTH) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free ALTH Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ALTH stock logo

About Allos Therapeutics Stock (NASDAQ:ALTH)

Allos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.

ALTH Stock News Headlines

November 2, 2021 | finance.yahoo.com
Laronde Expands Board of Directors with Leading Pharmaceutical Executives
See More Headlines
Receive ALTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ALTH
CUSIP
N/A
CIK
1097264
Web
www.allos.com
Phone
+1-303-4266262
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

ALTH Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Allos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allos Therapeutics investors own include E-House (China) Holdings Limite (EJ), DryShips (DRYS), Depomed (DEPO), Hongli Clean Energy Technologie (CETC), (CASC) (CASC), Alexco Resource (AXU), AXT (AXTI), AudioCodes (AUDC) and Amtech Systems (ASYS).

This page (NASDAQ:ALTH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends